Financial reports
ARS
2023 FY
Annual report to shareholders
18 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
7 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
26 Mar 24
8-K
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
6 Mar 24
8-K
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
31 Jan 24
8-K
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System
20 Dec 23
8-K
Regulation FD Disclosure
27 Nov 23
8-K
InspireMD Reports Third Quarter 2023 Financial Results and Provides
6 Nov 23
8-K
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS
1 Nov 23
8-K
Regulation FD Disclosure
12 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
2 Jan 24
S-8
Registration of securities for employees
6 Oct 23
424B3
Prospectus supplement
2 Jun 23
D
$42.17 mm in equity / options / securities to be acquired, sold $42.17 mm, 18 investors
30 May 23
S-3
Shelf registration
23 May 23
S-8
Registration of securities for employees
17 May 23
S-3
Shelf registration
3 Jun 22
25-NSE
Exchange delisting
15 Mar 22
S-8
Registration of securities for employees
13 Oct 21
25
Voluntary exchange delisting
7 Jun 21
Proxies
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEF 14A
Definitive proxy
28 Jul 23
PRE 14A
Preliminary proxy
18 Jul 23
DEFA14A
Additional proxy soliciting materials
5 Jul 22
DEF 14A
Definitive proxy
5 Jul 22
DEF 14A
Definitive proxy
12 Aug 21
DEFA14A
Additional proxy soliciting materials
22 Mar 21
DEFA14A
Additional proxy soliciting materials
9 Mar 21
Other
EFFECT
Notice of effectiveness
2 Jun 23
CORRESP
Correspondence with SEC
31 May 23
UPLOAD
Letter from SEC
30 May 23
EFFECT
Notice of effectiveness
15 Jun 22
CORRESP
Correspondence with SEC
13 Jun 22
UPLOAD
Letter from SEC
10 Jun 22
CERT
Certification of approval for exchange listing
7 Jun 21
CERT
Certification of approval for exchange listing
21 May 21
EFFECT
Notice of effectiveness
21 Apr 21
CORRESP
Correspondence with SEC
20 Apr 21
Ownership
SC 13G/A
Rosalind Advisors, Inc.
25 Apr 24
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
4
Thomas J Kester
25 Jan 24
4
Patrick Verta
25 Jan 24
4
Shane Thomas Gleason
25 Jan 24
4
Andrea Tommasoli
25 Jan 24
4
Kathryn Arnold
25 Jan 24
4
Craig Shore
25 Jan 24